Abeona Therapeutics Inc EPS Q/Q
What is the EPS Q/Q of Abeona Therapeutics Inc?
The EPS Q/Q of Abeona Therapeutics Inc is -15.43%
What is the definition of EPS Q/Q?
Quarterly EPS growth rate, year over year, is the increase of the company’s EPS for the most recent quarter compared to the the same quarter in the previous year.
quarterly growth yoy (year over year)
The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS Q/Q of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with eps q/q similar to Abeona Therapeutics Inc
- Metlife Inc has EPS Q/Q of -15.61%
- EyePoint Pharmaceuticals Inc has EPS Q/Q of -15.52%
- Motus GI Inc has EPS Q/Q of -15.50%
- Evoke Pharma Inc has EPS Q/Q of -15.48%
- ageas SA/NV has EPS Q/Q of -15.46%
- Mohawk Industries has EPS Q/Q of -15.44%
- Abeona Therapeutics Inc has EPS Q/Q of -15.43%
- Travelers Companies has EPS Q/Q of -15.38%
- Marker Therapeutics has EPS Q/Q of -15.38%
- Theratechnologies has EPS Q/Q of -15.38%
- Niu Technologies has EPS Q/Q of -15.38%
- First National (Ontario) has EPS Q/Q of -15.38%
- Coupa Software Inc has EPS Q/Q of -15.38%